Suppression of BCL6 function by HDAC inhibitor mediated acetylation and chromatin modification enhances BET inhibitor effects in B-cell lymphoma cells

Multiple genetic aberrations in the regulation of BCL6, including in acetyltransferase genes, occur in clinically aggressive B-cell lymphomas and lead to higher expression levels and activity of this transcriptional repressor. BCL6 is, therefore, an attractive target for therapy in aggressive lympho...

Descripción completa

Detalles Bibliográficos
Autores principales: Cortiguera, María G., García-Gaipo, Lorena, Wagner, Simon D., León, Javier, Batlle-López, Ana, Delgado, M. Dolores
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848194/
https://www.ncbi.nlm.nih.gov/pubmed/31712669
http://dx.doi.org/10.1038/s41598-019-52714-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848194/
https://www.ncbi.nlm.nih.gov/pubmed/31712669
http://dx.doi.org/10.1038/s41598-019-52714-4

Ejemplares similares